Flavanone

Flavanone

SCHEMBL980197

O=c1cc(-c2ccccc2)oc2cc(O)c(O)cc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 6/20 1.00
KDM4E B2RXH2 6/20 1.00
HSD17B10 Q99714 6/20 1.00
MAPT P10636 6/20 1.00
HPGD P15428 6/20 1.00
SMN1; SMN2 Q16637 5/20 1.00
CYP19A1 P11511 4/20 1.00
ALOX15 P16050 4/20 1.00
ALOX12 P18054 2/20 1.00
CASP1 P29466 1/20 1.00
CASP7 P55210 1/20 1.00
ALDH1A1 P00352 6/20 0.72
CYP2C19 P33261 3/20 0.72
CYP2D6 P10635 2/20 0.72
FTO Q9C0B1 4/20 0.69
CYP1B1 Q16678 4/20 0.69
PKM P14618 3/20 0.69
ABCB1 P08183 3/20 0.69
CYP1A2 P05177 3/20 0.69
MAOB P27338 3/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Flavanone SCHEMBL29678059 1.00 TP53 (1.00) TP53KDM4EHSD17B10MAPTHPGD
SCHEMBL31238423 0.87 KDM4E (0.76) TP53KDM4EHSD17B10MAPTHPGD
SCHEMBL3515838 0.87 HPGD (0.77) TP53KDM4EHSD17B10MAPTHPGD
SCHEMBL31552891 0.87 HPGD (0.77) TP53KDM4EHSD17B10MAPTHPGD
SCHEMBL4981350 0.86 MAPT (0.76) TP53KDM4EHSD17B10MAPTHPGD
SCHEMBL31238518 0.85 KDM4E (0.72) TP53KDM4EHSD17B10MAPTHPGD
SCHEMBL25201659 0.84 KDM4E (0.73) TP53KDM4EHSD17B10MAPTHPGD
Flavanone SCHEMBL5273130 0.84 KDM4E (0.76) TP53KDM4EHSD17B10MAPTHPGD
SCHEMBL4648917 0.84 KDM4E (1.00) TP53KDM4EHSD17B10MAPTHPGD
SCHEMBL25202745 0.84 MAPT (0.72) TP53KDM4EHSD17B10MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230119060-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING, AS ACTIVE INGREDIENT, COMPLEX OF BIGUANIDE-BASED COMPOUND AND FLAVONE, HYDROXYFLAVONE, FLAVANONE, FLAVONE DERIVATIVE, HYDROXYFLAVONE DERIVATIVE, OR FLAVANONE DERIVATIVE MEDIENCE CO., LTD. (KR) 2023-04-20 US claimed
WO-2023064318-A1 BIPHASIC COMPOSITIONS COMPRISING ONE OR BOTH OF CARBONATE AND PHOSPHATE Natural Extraction Systems, LLC (US) 2023-04-20 WO claimed
WO-2022255765-A1 NOVEL FLUORINE-SUBSTITUTED FLAVONOID DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ALLERGIC DISEASES, COMPRISING SAME 주식회사 에즈큐리스 2022-12-08 WO claimed
US-20220249431-A1 ANTIMYCOTIC Karl-Franzens-Universität Graz (AT) 2022-08-11 US claimed
EP-4003522-A1 ANTIMYCOTIC Karl-Franzens-Universität Graz (AT) 2022-06-01 EP claimed
WO-2021042001-A1 COMPOSITIONS AND METHODS RELATED TO DISSOLVED OXIDES Natural Extraction Systems, LLC (US) 2021-03-04 WO claimed
WO-2021013931-A1 ANTIMYCOTIC Karl-Franzens-Universität Graz (AT) 2021-01-28 WO claimed
EP-3769815-A1 ANTIMYCOTIC Karl-Franzens-Universität Graz (AT) 2021-01-27 EP claimed
EP-3302083-A1 MONO AND DI-GLYCERIDE ESTERS OF OMEGA-3 FATTY ACID EMULSIONS Mycell Technologies, LLC (US) 2018-04-11 EP claimed
CN-107645910-A Mono-and diglycerides of omega-3 fatty acid emulsions 麦赛尔科技有限责任公司 2018-01-30 CN claimed
WO-2010042728-A1 SMALL MOLECULE MODULATORS OF PRONGF UPTAKE CORNELL UNIVERSITY (US) 2010-04-15 WO claimed
WO-2010038153-A1 USE OF SOX TRANSCRIPTION FACTOR ACTI\\ATORS FOR STIMULATING CHONDROGENESIS THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2010-04-08 WO claimed
US-20060229262-A1 Pharmaceutical composition for treatment of infection with drug resistant bacterium and disinfectant TOMIHIKO HIGUCHI (JP) 2006-10-12 US claimed
US-6872771-B1 Tire with rubber containing flavone THE GOODYEAR TIRE & RUBBER COMPANY (US) 2005-03-29 US claimed
WO-2005020881-A2 COMPOSITIONS OF FLAVONOIDS AND FLAVONOID-CONTAINING EXTRACTS AND THE TREATMENT OF DISEASES SHANGHAI COMMAN PHARMACEUTICAL CO. (US) 2005-03-10 WO claimed
US-20050049206-A1 Compositions of flavonoids and flavonoid-containing extracts and the treatment of diseases SHANGHAI COMMAN PHARMACEUTICAL CO. LTD. (CN) 2005-03-03 US claimed
US-20040229825-A1 Pharmaceutical composition for treatment of infection with drug resistant bacterium and disinfectant ALPS PHARMACEUTICAL IND., CO., LTD. (JP) 2004-11-18 US claimed
JP-2003504327-A 2003-02-04 JP claimed
EP-1223928-A2 USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS Prendergast, Patrick Thomas (IE) 2002-07-24 EP claimed
WO-2001003681-A2 USE OF FLAVONES, COUMARINS AND RELATED COMPOUNDS TO TREAT INFECTIONS PRENDERGAST PATRICK T (IE) 2001-01-18 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220249431-A1 ANTIMYCOTIC ETF1, FOXM1, RIF1 TP53 2041/4885KDM4E 1705/4885HSD17B10 3005/4885
US-20230119060-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER CONTAINING, AS ACTIVE INGREDIENT, COMPLEX OF BIGUANIDE-BASED COMPOUND AND FLAVONE, HYDROXYFLAVONE, FLAVANONE, FLAVONE DERIVATIVE, HYDROXYFLAVONE DERIVATIVE, OR FLAVANONE DERIVATIVE SLC5A2, SLC5A1, SLC5A6 TP53 134/4885KDM4E 1490/4885HSD17B10 455/4885
US-20050049206-A1 Compositions of flavonoids and flavonoid-containing extracts and the treatment of diseases FNTA, COLGALT1, F3 TP53 3021/4885KDM4E 2663/4885HSD17B10 3661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.